Background Image
Menu

Latest News

AgTech startup CroBio raises €850k to reshape agriculture through enhanced microbes

12 February 2025

AgTech startup CroBio raises €850k to reshape agriculture through enhanced microbes

Cheshire-based CroBio, an AgTech startup on a mission to reshape the future of agriculture by harnessing the power of enhanced microbes, announced €805k in new funding to enhance their living soil amendment, a technology designed to improve nutrient retention, water retention...

Monument Therapeutics announces grant of Chinese patent in support of its MT1988 cognitive impairment associated with schizophrenia program.

21 January 2025

Monument Therapeutics announces grant of Chinese patent in support of its MT1988 cognitive impairment associated with schizophrenia program.

Manchester, UK, 21 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese...

Monument Therapeutics announces grant of Japanese patent in support of its MT1988 cognitive impairment associated with schizophrenia program

14 January 2025

Monument Therapeutics announces grant of Japanese patent in support of its MT1988 cognitive impairment associated with schizophrenia program

Manchester, UK, 14 January 2025 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of...

Boehringer Ingelheim acquires fourth license for the development of novel antibody based cancer treatments from Oxford BioTherapeutics

13 January 2025

Boehringer Ingelheim acquires fourth license for the development of novel antibody based cancer treatments from Oxford BioTherapeutics

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised an option for...

Maxwellia announces strategic leadership appointments to propel future growth

7 January 2025

Maxwellia announces strategic leadership appointments to propel future growth

Alderley Park, Cheshire, UK – Monday 6 January 2025 – Maxwellia, the female founded pioneering consumer healthcare company, is pleased to announce two significant additions to its leadership team. Candice Brett has been appointed as Chief Financial Officer (CFO), and Colin...

Maxwellia launches unexpected menstrual health campaign following concerning survey results

27 November 2024

Maxwellia launches unexpected menstrual health campaign following concerning survey results

• New survey released today reveals 56% of people feel unsure about the phases of the menstrual cycle … • 66% of participants said they lacked confidence in explaining the hormonal changes that occur during the different phases of the cycle … • Heavy period brand, Evana® creates...

Monument Therapeutics launches first clinical study of MT1988, a novel treatment for cognitive impairment associated with schizophrenia

26 November 2024

Monument Therapeutics launches first clinical study of MT1988, a novel treatment for cognitive impairment associated with schizophrenia

MANCHESTER, England, Nov. 26, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targeting cognitive impairment associated with...

Monument Therapeutics announces appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to guide schizophrenia program

19 November 2024

Monument Therapeutics announces appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to guide schizophrenia program

MANCHESTER, England, Nov. 19, 2024 /PRNewswire/ -- Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), is pleased to announce the addition of three distinguished experts...

Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant

7 November 2024

Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant

Apex Molecular Limited announces the appointment of Dr Jason Tierney as a medicinal chemistry consultant to work on their external customer medicinal chemistry drug discovery projects. Jason is an experienced Drug Hunter, having over 25 years’ experience in Drug Discovery, both...

Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth

15 October 2024

Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth

Manchester, UK, 15 October 2024 - Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation. The new investment builds on equity and non-dilutive funding announced in...